Update
Trellus Health plc has confirmed its cash runway has been extended to August 11, 2026, and is progressing well with discussions for a potential sale of certain company assets, including its US operating subsidiary, Trellus Health Inc. The company's ordinary shares remain suspended from trading on AIM since May 8, 2026, due to ongoing uncertainty regarding its financial position, with no certainty of a concluded transaction or further funding.
Select text to share a quote on X · sign in to keep highlights & notes in your TRLS notes
Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, confirms that, further to the Company's announcement of 19 June 2026, the Company's cash runway has been extended to 11 August 2026.
The Board has, over recent weeks and in conjunction with its corporate restructuring advisers, continued to progress a potential sale of certain Company assets including the shares in Trellus Health Inc., the Company's US operating subsidiary. Those discussions are well advanced. There can be no certainty that any transaction will be concluded or further funding will be forthcoming nor as to terms thereon. The Board also continues to take action to protect wider stakeholders' interests.
The Company's ordinary shares remain suspended from trading on AIM since 8 May 2026 due to the ongoing uncertainty regarding the Company's financial position.
Further announcements will be made as appropriate.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.